PERSONALIZED TREATMENT OF OPHTHALMOLOGIC DISEASES

• Main Authors: JEFFERY R WILLIS, AARON OSBORNE, LIN HUGH, DAVID ANDREW SILVERMAN, ROBERT JAMES WEIKERT
• Format: Patent
• Language: English; Japanese
• Published: 05.09.2023
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide new treatments that target additional pathways and lead to reduced burden of intravitreal injections, to address high unmet medical need in diabetic macular edema.SOLUTION: The present invention provides bispecific antibodies which bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases such as neovascular AMD (nAMD) (also known as choroidal neovascularization [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).SELECTED DRAWING: Figure 1 【課題】糖尿病性黄斑浮腫の満たされていない高い医療ニーズに対処するために、追加の経路を標的とし、硝子体内注入の負担を軽減する新しい治療法を提供する。【解決手段】本発明は、新生血管ＡＭＤ（ｎＡＭＤ）（加齢黄斑変性症［ＡＭＤ］に続発する脈絡膜血管新生［ＣＮＶ］またはウェット型ＡＭＤとしても知られる）、糖尿病性網膜症、特に、糖尿病性黄斑浮腫（ＤＭＥ）または網膜静脈閉塞症（ＲＶＯ）に続発する黄斑浮腫などの眼科の血管疾患の治療に使用するためのＶＥＧＦおよびＡＮＧ２に結合する二重特異性抗体を提供する。【選択図】図１